Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan Liposome Regimens vs Nab-paclitaxel Plus Gemcitabine in Untreated Metastatic Pancreatic Adenocarcinoma
NCT05047991Phase 2Unknown
- Sponsor
- CSPC Ouyi Pharmaceutical
- Start
- Oct 2021
- Primary completion
- Nov 2023
- Modality
- Lipid-based Nanoparticles, Small Molecules
01
Overview
Phase 2, randomised, open-label trial of irinotecan liposome injection in pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by CSPC Ouyi Pharmaceutical. Primary endpoint: Progression-Free Survival up to 12 months. Status: unknown.
02
Drugs
irinotecan liposome injection
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT05047991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05047991.